Exact Sciences Corporation (NASDAQ:EXAS) tinted gains of +2.67% (+2.29 points) to US$87.91. The volume of 1.75 Million shares climbed down over an trading activity of 1.84 Million shares. EPS ratio determined by looking at last 12 month figures is -2.22. Over the same time span, the stock marked US$86.63 as its best level and the lowest price reached was US$37.36. The corporation has a market cap of US$10.78 Billion.
Exact Sciences Corporation (NASDAQ:EXAS)’s earnings per share has been growing at a -18.6 percent rate over the past 5 year when average revenue increase was noted as 129.9 percent. The return on equity ratio or ROE stands at -21.4 percent while most common profitability ratio return on investment (ROI) was -46.3 percent. The company’s institutional ownership is monitored at 93.1 percent. The company’s net profit margin has achieved the current level of -35.8 percent and possesses 74.1 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 8 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 3 think it is Hold. Recently, analysts have updated the overall rating to 1.62. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is worth US$247.77 Million and has recently risen 3.35% to US$2.47. The latest exchange of 0.41 Million shares is below its average trading activity of 2.06 Million shares. The day began at US$2.38 but the price moved to US$2.38 at one point during the trading and finally capitulating to a session high of US$2.46. The stock tapped a 52-week high of US$4.05 while the mean 12-month price target for the shares is US$8.17.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 3.98, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown -9.6%. With an institutional ownership near 49.9%, it carries an earnings per share ratio of -0.25.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 5 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.83.